Triveni Bio is a clinical-stage biotechnology company in Watertown, Massachusetts building first-in-class antibody therapeutics for immunological and inflammatory (I&I) diseases. Born from the 2023 merger of Amagma Therapeutics and Modify Therapeutics, the company pairs a genetics-informed approach with advanced antibody engineering to target root-cause biology rather than just downstream inflammation. Its lead program, TRIV-509, is a half-life-extended monoclonal antibody that inhibits active kallikreins 5 and 7 (KLK5/7) and is in a global Phase 2 proof-of-concept study for moderate-to-severe atopic dermatitis. Backed by roughly $223M across Series A and Series B rounds, Triveni aims to repair the skin barrier and break what it calls efficacy ceilings in dermatology and beyond.
Vishal Patel is the co-founder and CEO of Triveni Bio, a Watertown, Massachusetts biotech betting that genetics, not trial-and-error, should decide which antibodies reach patients with immune and inflammatory diseases. He stitched the company together from a two-startup merger, raised more than $200 million across Series A and B rounds, and pointed its lead programs at the skin enzymes behind atopic dermatitis. A Harvard PhD and MIT MBA who once helped draft healthcare legislation on Capitol Hill and still serves as a US Navy reservist, Patel runs a lab while keeping a foot in venture as an Atlas advisor.